Related Experiment Video
Updated: Aug 11, 2025

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Intervention with Therapeutic Agents, Understanding the Path to Remission in Type 2 Diabetes: Part 1
Shuai Hao1, Guillermo E Umpierrez2, Tanicia Daley1
1Division of Pediatric Endocrinology, Children's Healthcare of Atlanta, Emory University School of Medicine, 1400 Tullie Road Northeast, Atlanta, GA 30329, USA.
Abstract:
Type 2 diabetes is characterized by progressive decline in pancreatic β-cell function. Studies in adult subjects with newly diagnosed type 2 diabetes have reported that intensive insulin therapy followed by various antihyperglycemic medications can delay β-cell decline. However, this improvement is lost after cessation of therapy. In contrast, youth with type 2 diabetes experience a more rapid loss in β-cell function compared with adults and have loss of β-cell function despite being on insulin and other antihyperglycemic medications. In part one of this two-part review, we discuss studies aiming to achieve diabetes remission with insulin and oral antidiabetic medications.
Insights
Type 2 diabetes in youth rapidly impairs pancreatic beta-cell function. Intensive therapies may temporarily delay decline, but remission is challenging with current medications.
Area of Science:
- Endocrinology
- Metabolic disorders
- Diabetes research
Background:
- Type 2 diabetes involves progressive pancreatic beta-cell dysfunction.
- Adults with type 2 diabetes may delay beta-cell decline with intensive therapy, but benefits cease upon treatment withdrawal.
- Youth with type 2 diabetes exhibit faster beta-cell function loss than adults, even with medication.
Purpose of the Study:
- To review studies on achieving diabetes remission in youth.
- To evaluate the efficacy of insulin and oral antidiabetic medications in preserving beta-cell function.
Main Methods:
- Review of existing studies on type 2 diabetes treatment in youth.
- Analysis of therapeutic strategies involving insulin and oral antidiabetic agents.
Main Results:
- Youth with type 2 diabetes show accelerated beta-cell decline compared to adults.
- Current antihyperglycemic medications, including insulin, do not prevent beta-cell loss in this population.
- Therapeutic improvements are often temporary and lost upon cessation.
Conclusions:
- Achieving sustained diabetes remission in youth with type 2 diabetes remains a significant challenge.
- Further research is needed to develop effective long-term strategies for preserving beta-cell function in pediatric populations.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

